Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8366)
All Articles published online
|
Publishing Process of This Article
|
Mar 7, 2014 (publication date) through Feb 7, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236 [PMID: 24605022 DOI: 10.3748/wjg.v20.i9.2224] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i9/2224.htm |
| Number | Citing Articles |
| 1 |
Hirosato Ebiike, Naoki Taka, Masayuki Matsushita, Masayuki Ohmori, Kyoko Takami, Ikumi Hyohdoh, Masami Kohchi, Tadakatsu Hayase, Hiroki Nishii, Kenji Morikami, Yoshito Nakanishi, Nukinori Akiyama, Hidetoshi Shindoh, Nobuya Ishii, Takehito Isobe, Hiroharu Matsuoka. Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor. Journal of Medicinal Chemistry 2016; 59(23): 10586 doi: 10.1021/acs.jmedchem.6b01156
|
| 2 |
Thomas Chaigneau, Lina Aguilera Munoz, Caroline Oger, Clémence Gourdeau, Olivia Hentic, Lucie Laurent, Nelly Muller, Marco Dioguardi Burgio, Marie-Pauline Gagaille, Philippe Lévy, Vinciane Rebours, Pascal Hammel, Louis de Mestier. Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens. Therapeutic Advances in Medical Oncology 2023; 15 doi: 10.1177/17588359231163776
|
| 3 |
Zu T. Shen, Alexander B. Sigalov. Novel TREM-1 Inhibitors Attenuate Tumor Growth and Prolong Survival in Experimental Pancreatic Cancer. Molecular Pharmaceutics 2017; 14(12): 4572 doi: 10.1021/acs.molpharmaceut.7b00711
|
| 4 |
Cristoforo Grasso, Gerrit Jansen, Elisa Giovannetti. Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Critical Reviews in Oncology/Hematology 2017; 114: 139 doi: 10.1016/j.critrevonc.2017.03.026
|
| 5 |
Lucas de Sousa Cavalcante, Gisele Monteiro. Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. European Journal of Pharmacology 2014; 741: 8 doi: 10.1016/j.ejphar.2014.07.041
|
| 6 |
Chih‐Chung Hsu, Keng‐Hao Liu, Pei‐Hung Chang, Ping‐Tsung Chen, Chia‐Yen Hung, Shun‐Wen Hsueh, Kun‐Yun Yeh, Yen‐Yang Chen, Chang‐Hsien Lu, Yu‐Shin Hung, Wen‐Chi Chou. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second‐line palliative chemotherapy. Journal of Gastroenterology and Hepatology 2020; 35(10): 1694 doi: 10.1111/jgh.14926
|
| 7 |
Shuo Yu, Min Wang, Hang Zhang, Xingjun Guo, Renyi Qin. Resistance to gemcitabine is mediated by the circ_0036627/miR‐145/S100A16 axis in pancreatic cancer. Journal of Cellular and Molecular Medicine 2024; 28(12) doi: 10.1111/jcmm.18444
|
| 8 |
Shengqi Qin, Yiming Deng, Jianshe Li, Zhongtao Zhang.
A bioengineered murine model using CD24
+
CD44
+
pancreatic cancer stem cells for chemotherapy study
. Biomedical Materials 2014; 10(1): 015004 doi: 10.1088/1748-6041/10/1/015004
|
| 9 |
Arsen Osipov, Nicholas Nissen, Joanne Rutgers, Deepti Dhall, Jason Naziri, Shefali Chopra, Quanlin Li, Andrew Eugene Hendifar, Richard Tuli. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. Annals of Surgical Oncology 2017; 24(12): 3674 doi: 10.1245/s10434-017-6076-z
|
| 10 |
Andrea Wang-Gillam, Richard A. Hubner, Jens T. Siveke, Daniel D. Von Hoff, Bruce Belanger, Floris A. de Jong, Beloo Mirakhur, Li-Tzong Chen. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. European Journal of Cancer 2019; 108: 78 doi: 10.1016/j.ejca.2018.12.007
|
| 11 |
Martina Catalano, Giandomenico Roviello, Raffaele Conca, Alberto D’Angelo, Valeria Emma Palmieri, Benedetta Panella, Roberto Petrioli, Anna Ianza, Stefania Nobili, Enrico Mini, Monica Ramello. Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. Current Cancer Drug Targets 2020; 20(11): 887 doi: 10.2174/1568009620999200918122426
|
| 12 |
Satya Das, Jordan Berlin, Dana Cardin. Harnessing the Immune System in Pancreatic Cancer. Current Treatment Options in Oncology 2018; 19(10) doi: 10.1007/s11864-018-0566-5
|
| 13 |
Oliver A. Kent, Maria-Jose Sandi, Robert Rottapel. Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition. Small GTPases 2019; 10(6): 441 doi: 10.1080/21541248.2017.1337545
|
| 14 |
Anders Ekström, Eva Brun, Jakob Eberhard, Mikael Segerlantz. Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer. Acta Oncologica 2021; 60(12): 1580 doi: 10.1080/0284186X.2021.1973680
|
| 15 |
Catherine Burkhart, Daria Fleyshman, Rachael Kohrn, Mairead Commane, Jennifer Garrigan, Vadim Kurbatov, Ilya Toshkov, Rajesh Ramachandran, Laura Martello, Katerina V. Gurova. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget 2014; 5(22): 11038 doi: 10.18632/oncotarget.2701
|
| 16 |
Mamoon Ur Rashid, Ishtiaq Hussain, Sundas Jehanzeb, Waqas Ullah, Saeed Ali, Akriti Gupta Jain, Ranjeet Kumar, Neelam Khetpal, Sarfraz Ahmad. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. 2019; : 57 doi: 10.1016/B978-0-12-817661-0.00005-6
|
| 17 |
Wilfried Tröger, Danijel Galun, Marcus Reif, Agnes Schumann, Nikola Stanković, Miroslav Milićević. Quality of Life of Patients With Advanced Pancreatic Cancer During Treatment With Mistletoe. Deutsches Ärzteblatt international 2014; doi: 10.3238/arztebl.2014.0493
|
| 18 |
Yong Pan, Patrea Rhea, Lin Tan, Carrie Cartwright, Ho-Jeong Lee, Murali K. Ravoori, Crandell Addington, Mihai Gagea, Vikas Kundra, Sun-Jin Kim, Robert A. Newman, Peiying Yang. PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Investigational New Drugs 2015; 33(2): 271 doi: 10.1007/s10637-014-0190-6
|
| 19 |
Cindy Neuzillet, Annemilaï Tijeras-Raballand, Philippe Bourget, Jérôme Cros, Anne Couvelard, Alain Sauvanet, Marie-Pierre Vullierme, Christophe Tournigand, Pascal Hammel. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacology & Therapeutics 2015; 155: 80 doi: 10.1016/j.pharmthera.2015.08.006
|
| 20 |
Jiujie Cui, Shukui Qin, Yuhong Zhou, Shuang Zhang, Xiaofeng Sun, Mingjun Zhang, Jiuwei Cui, Weijia Fang, Kangsheng Gu, Zhihua Li, Jufeng Wang, Xiaobing Chen, Jun Yao, Jun Zhou, Gang Wang, Yuxian Bai, Juxiang Xiao, Wensheng Qiu, Bangmao Wang, Tao Xia, Chunyue Wang, Li Kong, Jiajun Yin, Tao Zhang, Xionghu Shen, Deliang Fu, Chuntao Gao, Huan Wang, Quanren Wang, Liwei Wang. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial. Signal Transduction and Targeted Therapy 2024; 9(1) doi: 10.1038/s41392-024-01948-4
|
| 21 |
Giuseppe Aprile, Francesca V. Negri, Francesco Giuliani, Elisa De Carlo, Davide Melisi, Francesca Simionato, Nicola Silvestris, Oronzo Brunetti, Francesco Leone, Donatella Marino, Daniele Santini, Emanuela Dell’Aquila, Tea Zeppola, Marco Puzzoni, Mario Scartozzi. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology 2017; 115: 1 doi: 10.1016/j.critrevonc.2017.03.025
|
| 22 |
Ana De Jesus-Acosta, Amol Narang, Lauren Mauro, Joseph Herman, Elizabeth M. Jaffee, Daniel A. Laheru. Abeloff's Clinical Oncology. 2020; : 1342 doi: 10.1016/B978-0-323-47674-4.00078-5
|
| 23 |
M. Bupathi, D. H. Ahn, C. Wu, K. K. Ciombor, J. A. Stephens, J. Reardon, D. A. Goldstein, T. Bekaii-Saab. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Medical Oncology 2016; 33(4) doi: 10.1007/s12032-016-0753-9
|
| 24 |
Angélique Vienot, Guillaume Beinse, Christophe Louvet, Louis de Mestier, Aurélia Meurisse, Francine Fein, Bruno Heyd, Denis Cleau, Christelle d’Engremont, Anne-Claire Dupont-Gossart, Zaher Lakkis, Christophe Tournigand, Olivier Bouché, Benoît Rousseau, Cindy Neuzillet, Franck Bonnetain, Christophe Borg, Dewi Vernerey. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. JNCI: Journal of the National Cancer Institute 2017; 109(10) doi: 10.1093/jnci/djx037
|
| 25 |
Bomi Kim, Jaihwan Kim, Soomin Yang, Jinwoo Ahn, Kwangrok Jung, Jong-Chan Lee, Jin-Hyeok Hwang. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. World Journal of Gastrointestinal Oncology 2025; 17(2): 100167 doi: 10.4251/wjgo.v17.i2.100167
Abstract(63) |
Core Tip(48) |
Full Article(HTML)(209)
|
Full Article with Cover (PDF)-63990K(24)
|
Audio-409K(2)
|
Peer-Review Report-209K(17)
|
Answering Reviewers-404K(14)
|
Supplementary Material-211K(16)
|
Full Article (PDF)-63731K(21)
|
Full Article (XML)-98K(13)
|
Times Cited (0)
|
Total Visits (829)
|
Open
|
| 26 |
Arndt Vogel, Fortunato Ciardiello, Richard A. Hubner, Jean-Frédéric Blanc, Alfredo Carrato, Yoojung Yang, Dipen A. Patel, Varun Ektare, Floris A. de Jong, Sharlene Gill. Post-gemcitabine therapy for patients with advanced pancreatic cancer – A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. Cancer Treatment Reviews 2016; 50: 142 doi: 10.1016/j.ctrv.2016.09.001
|
| 27 |
Andrew H. Ko. Clinical Management. The Cancer Journal 2017; 23(6): 355 doi: 10.1097/PPO.0000000000000294
|
| 28 |
L. Gutierrez-Sainz, D. Viñal, J. Villamayor, D. Martinez-Perez, J. A. Garcia-Cuesta, I. Ghanem, A. Custodio, J. Feliu. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. Clinical and Translational Oncology 2021; 23(9): 1838 doi: 10.1007/s12094-021-02589-7
|
| 29 |
Herbert Hurwitz, Eric Van Cutsem, Johanna Bendell, Manuel Hidalgo, Chung-Pin Li, Marcelo Garrido Salvo, Teresa Macarulla, Vaibhav Sahai, Ashwin Sama, Edward Greeno, Kenneth H. Yu, Chris Verslype, Fitzroy Dawkins, Chris Walker, Jason Clark, Eileen M. O’Reilly. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Investigational New Drugs 2018; 36(4): 683 doi: 10.1007/s10637-018-0580-2
|
| 30 |
Manish Manrai, T V S V G K Tilak, Saurabh Dawra, Sharad Srivastava, Anupam Singh. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World Journal of Gastroenterology 2021; 27(39): 6572-6589 doi: 10.3748/wjg.v27.i39.6572
|
| 31 |
Aurélien Lambert, Lilian Schwarz, Ivan Borbath, Aline Henry, Jean-Luc Van Laethem, David Malka, Michel Ducreux, Thierry Conroy. An update on treatment options for pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology 2019; 11 doi: 10.1177/1758835919875568
|
| 32 |
Tai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, Chung-Pin Li, Li-Yuan Bai, Nai-Jung Chiang, Shih-Chang Chuang, Yan-Shen Shan, De-Chuan Chan, Li-Tzong Chen, Chia-Jui Yen, Cheng-Ming Peng, Yen-Yang Chen, Jen-Shi Chen, Wen-Chi Chou. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study. Therapeutic Advances in Medical Oncology 2021; 13 doi: 10.1177/17588359211058255
|
| 33 |
Akseli Hemminki, Camilla Heiniö. Oncolytic adenovirus for treatment of malignant ascites. Molecular Therapy - Oncolytics 2022; 26: 302 doi: 10.1016/j.omto.2022.07.010
|
| 34 |
Constantin Maier-Stocker, Michael Bitzer, Nisar P. Malek, Ruben R. Plentz. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scandinavian Journal of Gastroenterology 2014; 49(12): 1480 doi: 10.3109/00365521.2014.978816
|
| 35 |
Alica K. Beutel, Lena Schütte, Jeanette Scheible, Elodie Roger, Martin Müller, Lukas Perkhofer, Annika M. T. U. Kestler, Johann M. Kraus, Hans A. Kestler, Thomas F. E. Barth, Johannes Lemke, Marko Kornmann, Thomas J. Ettrich, Johann Gout, Thomas Seufferlein, Alexander Kleger. A Prospective Feasibility Trial to Challenge Patient–Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Cancers 2021; 13(11): 2539 doi: 10.3390/cancers13112539
|
| 36 |
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew Dean, Yan-Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, Jean F Blanc, Richard A Hubner, Chang-Fang Chiu, Gilberto Schwartsmann, Jens T Siveke, Fadi Braiteh, Victor Moyo, Bruce Belanger, Navreet Dhindsa, Eliel Bayever, Daniel D Von Hoff, Li-Tzong Chen, Clarence Adoo, Thomas Anderson, Jamil Asselah, Alan Azambuja, Carolyn Bampton, Carlos Henrique Barrios, Tanios Bekaii-Saab, Melichar Bohuslav, David Chang, Jen-Shi Chen, Yeu-Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csoszi, Antonio Cubillo, Linda DeMarco, Maike de Wit, Tomislav Dragovich, William Edenfield, Luis Enrique Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Iaffaioli, Jitka Jakesova, Zsuzsanna Kahan, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, Istvan Lang, Fa-Chyi Lee, Kuan-Der Lee, Lara Lipton, Wen Wee Ma, Laszlo Mangel, Raul Mena, Daniel Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gallego Plazas, Cooray Prasad, Kun-Ming Rau, Jean-Luc Raoul, Donald Richards, Paul Ross, Luis Schlittler, Martin Smakal, Vladimira Stahalova, Cora Sternberg, Thomas Seufferlein, Niall Tebbutt, Jeferson Jose Vinholes, Raymond Wadlow, Milkos Wenczl, Mark Wong. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. The Lancet 2016; 387(10018): 545 doi: 10.1016/S0140-6736(15)00986-1
|
| 37 |
Sabrina Gloria Giulia Testoni, Maria Chiara Petrone, Michele Reni, Clelia Di Serio, Paola Maria Rancoita, Gemma Rossi, Gianpaolo Balzano, Walter Linzenbold, Markus Enderle, Emanuel Della-Torre, Francesco De Cobelli, Massimo Falconi, Gabriele Capurso, Paolo Giorgio Arcidiacono. EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case–control study. Endoscopic Ultrasound 2022; 11(5): 383 doi: 10.4103/EUS-D-21-00200
|
| 38 |
Cindy Neuzillet, Sébastien Gaujoux, Nicolas Williet, Jean-Baptiste Bachet, Lucile Bauguion, Laurianne Colson Durand, Thierry Conroy, Laetitia Dahan, Marine Gilabert, Florence Huguet, Lysiane Marthey, Julie Meilleroux, Louis de Mestier, Bertrand Napoléon, Fabienne Portales, Antonio Sa Cunha, Lilian Schwarz, Julien Taieb, Benoist Chibaudel, Olivier Bouché, Pascal Hammel. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Digestive and Liver Disease 2018; 50(12): 1257 doi: 10.1016/j.dld.2018.08.008
|
| 39 |
Jie Chen, Linli Chen, Jianping Yu, Yanmei Xu, Xiaohui Wang, Ziqian Zeng, Ning Liu, Fan Xu, Shu Yang. Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities. Molecular Medicine Reports 2018; doi: 10.3892/mmr.2018.9638
|
| 40 |
Li Xiao, Ulrike Erb, Kun Zhao, Thilo Hackert, Margot Zöller. Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. OncoImmunology 2017; 6(6) doi: 10.1080/2162402X.2017.1319044
|
| 41 |
Andrew H. Ko, Tanios Bekaii-Saab, Jessica Van Ziffle, Olga M. Mirzoeva, Nancy M. Joseph, AmirAli Talasaz, Peter Kuhn, Margaret A. Tempero, Eric A. Collisson, R. Kate Kelley, Alan P. Venook, Elizabeth Dito, Anna Ong, Sharvina Ziyeh, Ryan Courtin, Regina Linetskaya, Sanaa Tahiri, W. Michael Korn. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research 2016; 22(1): 61 doi: 10.1158/1078-0432.CCR-15-0979
|
| 42 |
Ferdinando De Vita, Jole Ventriglia, Antonio Febbraro, Maria Maddalena Laterza, Alessio Fabozzi, Beatrice Savastano, Angelica Petrillo, Anna Diana, Guido Giordano, Teresa Troiani, Giovanni Conzo, Gennaro Galizia, Fortunato Ciardiello, Michele Orditura. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2671-9
|
| 43 |
Amrallah A. Mohammed, Omar Al-Zahrani, Fifi Mostafa Elsayed. The application of the Glasgow prognostic score to predict the survival in patients with metastatic pancreatic carcinoma. Indian Journal of Palliative Care 2022; 28: 406 doi: 10.25259/IJPC_81_2021
|
| 44 |
Tamara M H Gall, Maria Tsakok, Harpreet Wasan, Long R Jiao. Pancreatic cancer: current management and treatment strategies. Postgraduate Medical Journal 2015; 91(1080): 601 doi: 10.1136/postgradmedj-2014-133222
|
| 45 |
Alexander B. Sigalov. Protein-Protein Interactions in Human Disease, Part B. Advances in Protein Chemistry and Structural Biology 2018; 111: 61 doi: 10.1016/bs.apcsb.2017.06.004
|
| 46 |
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, Syed A. Ahmad, Andrew M. Waters. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1402128
|
| 47 |
Krisha Amin, Hamza Khan, Larry R. Hearld, Daniel I. Chu, Victoria Prete, Krista R. Mehari, Martin J. Heslin, Annabelle L. Fonseca. Association between Rural Residence and Processes of Care in Pancreatic Cancer Treatment. Journal of Gastrointestinal Surgery 2023; 27(10): 2155 doi: 10.1007/s11605-023-05764-z
|
| 48 |
Ghazaleh Pourali, Ghazaleh Donyadideh, Shima Mehrabadi, Fiuji Hamid, Seyed Mahdi Hassanian, Gordon A. Ferns, Majid Khazaei, Amir Avan. Recent Advances in Nanocarriers for Pancreatic Cancer Therapy. 2024; : 345 doi: 10.1016/B978-0-443-19142-8.00008-5
|
| 49 |
Bianca Varzaru, Razvan A. Iacob, Adina E. Croitoru, Speranta M. Iacob, Cristina E. Radu, Stefania M. Dumitrescu, Cristian Gheorghe. Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma. Cancers 2023; 15(13): 3500 doi: 10.3390/cancers15133500
|
| 50 |
Shuangshuang Lu, Tasqeen Ahmed, Pan Du, Yaohe Wang. Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. International Journal of Molecular Sciences 2017; 18(6): 1201 doi: 10.3390/ijms18061201
|
| 51 |
Yuan Li, Caiming Xu, Haiyong Han, Silvia Pascual-Sabater, Cristina Fillat, Ajay Goel. Aronia Berry Extract Modulates MYD88/NF-kB/P-Glycoprotein Axis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Pharmaceuticals 2024; 17(7): 911 doi: 10.3390/ph17070911
|